Bixiye
Notice of Medicare Non-Coverage (NOMNC) (PDF)
Natiijooyinka Raadinta
Soo bandhiga 1471 - 1480 ee natiijooyinka 4161
Bixiye
QP82R1-19 Pharmacy Benefit Update - $0 Insulin Member Cost-Share Benefit for Commercial Lines of Business
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP95-19 New Drug, Reyvow™ (lasmiditan) Will Require Prior Authorization (PA)
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP93-19 Provider Cost Data Update
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP99-19 Pharmacy Benefit Exclusion for Rapatha ®
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP96-19 Pharmacy Benefit Exclusion for PolivyTM, KanjintiTM, Evenity ®, BelrapzoTM, MvasiTM, Clinolipid 20%, Cisplatin, Heparin Sodium, and Selenious acid
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP94-19 MDH Syphilis Pregnancy Screening Guidelines
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP101-19 InterQual ® Level of Care Criteria for Concurrent Review Authorizations
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP100-19 Blue Distinction Center and Blue Distinction Center + Designations Being Applied to Ambulatory Surgical Centers for Spine, Knee and Hip Services
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019
Bixiye
QP97-19 Commercial Product Changes for 2020
Taariikhda uu dhaqangalayo Barnaamijka: Nov 27, 2019